Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life

BACKGROUND: Chronic prurigo (CPG) is a pruritic skin disease, characterized by an itch-scratch cycle and scarring. It reduces patients’ quality of life (QoL). Dupilumab is a monoclonal human IgG antibody that inhibits signaling of the interleukin 4 (IL-4) and interleukin 13 (IL-13) pathways through...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Clara, Hafner, Jürg, Schuermann, Manuel, Tanadini, Matteo, Trisconi, Nisia, Schmid-Grendelmeier, Peter, Kündig, Thomas, Nägeli, Mirjam, Brüggen, Marie-Charlotte, Guillet, Carole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Outcome Measures – Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614240/
https://www.ncbi.nlm.nih.gov/pubmed/37369187
http://dx.doi.org/10.1159/000531708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614240/
https://www.ncbi.nlm.nih.gov/pubmed/37369187
http://dx.doi.org/10.1159/000531708

Ejemplares similares